<SEC-DOCUMENT>0001161697-20-000226.txt : 20200526
<SEC-HEADER>0001161697-20-000226.hdr.sgml : 20200526
<ACCEPTANCE-DATETIME>20200526120905
ACCESSION NUMBER:		0001161697-20-000226
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200520
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200526
DATE AS OF CHANGE:		20200526

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			REPRO MED SYSTEMS INC
		CENTRAL INDEX KEY:			0000704440
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				133044880
		STATE OF INCORPORATION:			NY
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39086
		FILM NUMBER:		20908898

	BUSINESS ADDRESS:	
		STREET 1:		24 CARPENTER RD
		CITY:			CHESTER
		STATE:			NY
		ZIP:			10918
		BUSINESS PHONE:		845-469-2042

	MAIL ADDRESS:	
		STREET 1:		24 CARPENTER RD
		CITY:			CHESTER
		STATE:			NY
		ZIP:			10918
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form_8-k.htm
<DESCRIPTION>FORM 8-K CURRENT REPORT FOR 05-20-2020
<TEXT>
<HTML>
<HEAD>
</HEAD>
<TITLE></TITLE>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<DIV style="width:720px">
<BR>
<P style="margin:0" align=center><B>UNITED STATES</B></P>
<P style="margin:0" align=center><B>SECURITIES AND EXCHANGE COMMISSION</B></P>
<P style="margin:0" align=center><B>Washington, DC 20549</B></P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0; font-size:12pt" align=center><B>FORM 8-K</B></P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0; font-size:12pt" align=center><B>CURRENT REPORT</B></P>
<P style="margin:0; font-size:12pt" align=center><B>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B></P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0" align=center>Date of Report (Date of earliest event reported)&nbsp;&nbsp;&nbsp;<B><U>May 20, 2020</U></B></P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0; font-size:14pt" align=center><B><U>REPRO MED SYSTEMS, INC.</U></B></P>
<P style="margin:0" align=center>(Exact name of registrant as specified in its charter)</P>
<P style="margin:0" align=center>&nbsp;</P>
<TABLE style="margin-top:0; font-size:10pt" cellpadding=0 cellspacing=0 align=center>
<TR><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center><B><U>New York</U></B></P>
</TD><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center><B><U>0-12305</U></B></P>
</TD><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center><B><U>13-3044880</U></B></P>
</TD></TR>
<TR><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center>(State or other jurisdiction<BR>
of incorporation)</P>
</TD><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center>(Commission<BR>
File Number)</P>
</TD><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center>(IRS Employer<BR>
Identification No.)</P>
</TD></TR>
</TABLE>
<P style="margin:0" align=center><BR></P>
<TABLE style="margin-top:0; font-size:10pt" cellpadding=0 cellspacing=0 align=center>
<TR><TD style="margin-top:0" valign=top width=288><P style="margin:0" align=center><B><U>24 Carpenter Road, Chester, New York</U></B></P>
</TD><TD style="margin-top:0" valign=top width=96><P style="margin:0" align=center><B><U>10918</U></B></P>
</TD></TR>
<TR><TD style="margin-top:0" valign=top width=288><P style="margin:0" align=center>(Address of principal executive offices)</P>
</TD><TD style="margin-top:0" valign=top width=96><P style="margin:0" align=center>(Zip Code)</P>
</TD></TR>
</TABLE>
<P style="margin:0" align=center><BR></P>
<P style="margin:0" align=center>Registrant&rsquo;s telephone number, including area code&nbsp;&nbsp;&nbsp;<B><U>(845) 469-2042</U></B></P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0" align=center><U>not applicable</U></P>
<P style="margin:0" align=center>(Former name or former address, if changed since last report)</P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0; text-align: justify">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">[ &nbsp;] &nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">[ &nbsp;] &nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">[ &nbsp;] &nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">[ &nbsp;] &nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">Emerging growth company &nbsp;[_]</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &nbsp;[_]</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">Securities registered pursuant to Section 12(b) of the Act:</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="margin-top: 0px; font-size: 10pt"><TR height=0 style="font-size:1pt"><TD STYLE="width: 2.5in"></TD><TD STYLE="width: 2.5in"></TD><TD STYLE="width: 2.5in"></TD></TR>
<TR><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px"><U>Title of each class</U></P>
</TD><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px"><U>Trading symbol(s)</U></P>
</TD><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px"><U>Name of each exchange on which registered</U></P>
</TD></TR>
<TR><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px"><B>common stock, $0.01 par value</B></P>
</TD><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px"><B>KRMD</B></P>
</TD><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px"><B>NASDAQ Capital Market</B></P>
</TD></TR>
</TABLE>
<P style="margin:0; text-align: justify">&nbsp;</P>

<HR noshade align="center" width="100%" size="2"><p style='page-break-before:always'></p><PAGE><BR>

<P style="margin:0"><B>Item 8.01 Other Events.</B></P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify">On May 20, 2020, Repro Med Systems, Inc. d/b/a/ KORU Medical Products (the &ldquo;Company&rdquo;) entered
into a Settlement Agreement with EMED Technologies Corporation (&ldquo;EMED&rdquo;) to settle all claims in connection with all
pending litigation matters between them (the &ldquo;Claims&rdquo;). Pursuant to the Settlement Agreement, the Company issued to
EMED (i) 95,238 restricted stock units, vesting on May 21, 2020 and 95,238 restricted stock units vesting on January 1, 2021, and
(ii) an option to purchase up to 400,000 shares of the Company&rsquo;s common stock at an exercise price of $11.21 per share prior
to February 1, 2021, which can be settled in cash in lieu of common stock at the Company&rsquo;s sole discretion, provided that
the number of shares of common stock and/or amount of cash paid by the Company upon exercise will be capped at a value of $16.21
per share. The Settlement Agreement includes mutual releases and covenants not to sue for any claim arising before May 20, 2020
and the Company covenants not to challenge any EMED patents that were the subject of the Claims unless EMED asserts them in the
future against Company products.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify">On May 26, 2020, the Company issued a press release announcing the events set forth in this Current Report
on Form 8-K. A copy of the press release is furnished as Exhibit 99.1 hereto.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify"><U>Forward-looking Statements</U></P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify">This Current Report on Form 8-K and the attached press release may contain
forward-looking statements that involve risks and uncertainties. Actual results may differ materially. The potential risks
and uncertainties that could cause actual results to differ include, among others, those risks and uncertainties included
under the captions &ldquo;Risk Factors&rdquo; in our Annual Report on Form 10-K for the year ended December 31, 2019, as
amended, and our most recent Quarterly Report on Form 10-Q, which are on file with the SEC and are available on our website
at www.korumedical.com/investors and on the SEC website at www.sec.gov. All information provided in this Current Report
on Form 8-K and the attached press release is as of May 26, 2020.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0"><B>Item 9.01 Financial Statements and Exhibits.</B></P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0; text-align: justify">(d) Exhibits.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 720px">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 96"><U>Exhibit No.</U></TD>
    <TD STYLE="width: 624"><U>Description</U></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>99.1</TD>
    <TD><A HREF="ex_99-1.htm">Press release dated May 26, 2020</A></TD></TR>
</TABLE>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify"><BR></P>

<P style="margin:0" align=center><B>SIGNATURES</B></P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0; text-indent:0; text-align: justify">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<TABLE style="margin-top:0; font-size:10pt" cellpadding=0 cellspacing=0 width=100%>
<TR><TD style="margin-top:0" valign=top><P style="margin:0">&nbsp;</P>
</TD><TD style="margin-top:0" valign=top width=360 colspan=2><P style="margin:0">REPRO MED SYSTEMS, INC.<BR>
(Registrant)</P>
</TD></TR>
<TR><TD style="margin-top:0" valign=top><P style="margin:0">&nbsp;</P>
</TD><TD style="margin-top:0" valign=top width=24><P style="margin:0">&nbsp;</P>
</TD><TD style="margin-top:0" valign=top width=336><P style="margin:0">&nbsp;</P>
</TD></TR>
<TR><TD style="margin-top:0" valign=top><P style="margin:0">Date: &nbsp;<U>May 26, 2020</U></P>
</TD><TD style="margin-top:0" valign=top width=24><P style="margin:0">By:</P>
</TD><TD style="margin-top:0" valign=top width=336><P style="margin:0"><U>/s/ Karen Fisher</U></P>
</TD></TR>
<TR><TD style="margin-top:0" valign=top colspan=2><P style="margin:0">&nbsp;</P>
</TD><TD style="margin-top:0" valign=top width=336><P style="margin:0">Karen Fisher<BR>
Chief Financial Officer</P>
</TD></TR>
</TABLE>
<P style="margin:0"><BR></P>
<P style="margin:0" align=center>- 2 -</P>
<HR noshade align="center" width="100%" size="2">
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>ex_99-1.htm
<DESCRIPTION>PRESS RELEASE DATED MAY 26, 2020
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 11pt Times New Roman, Times, Serif">
<DIV style="width:6.5in">
<BR>
<P style="margin:0px" align=center><FONT STYLE="font-size: 10pt"><B>Exhibit 99.1</B></FONT></P>

<P style="margin:0px">&nbsp;</P>

<P style="margin:0px"><img src="koru_logo.jpg"></P>

<P style="margin:0px">&nbsp;</P>

<P style="margin:0px; font-size:11pt" align=center><B><U>FOR IMMEDIATE RELEASE</U></B></P>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px; font-size:11pt" align=center><B><U>KORU MEDICAL SYSTEMS AND EMED TECHNOLOGIES CORPORATION ANNOUNCE SETTLEMENT OF ALL PENDING LITIGATION</U></B></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-size:11pt; text-align: justify"><B>CHESTER, NY &ndash; May 26, 2020 &ndash; Repro Med Systems, Inc.
d/b/a KORU Medical Systems (NASDAQ: KRMD) (&ldquo;KORU Medical&rdquo;)</B> and EMED Technologies Corporation (&ldquo;EMED&rdquo;)
today announced the settlement of all ongoing litigation between the two companies, including patent, antitrust, unfair business
practice, and other business tort claims.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; font-size:11pt; text-align: justify">The agreement provides KORU Medical with freedom to operate under
EMED&rsquo;s existing patent portfolio, dismissal of all litigation with prejudice, and an equity payment by KORU Medical to EMED.&nbsp;</P>
<P style="margin:0px; text-align: justify"><BR></P>

<P style="margin:0px; font-size:11pt; text-align: justify"><B><U>About KORU Medical Systems</U></B></P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; font-size:11pt; text-align: justify">KORU Medical Systems manufactures and commercializes innovative
and easy-to-use specialty infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe
Infusion System currently includes the FREEDOM60<SUP>&reg;</SUP>&nbsp;and FreedomEdge<SUP>&reg;</SUP>&nbsp;Syringe Infusion
Drivers, Precision Flow Rate Tubing<SUP>&trade;</SUP>&nbsp;and HIgH-Flo Subcutaneous Safety Needle Sets<SUP>&trade;</SUP>.
These devices are used for infusions administered in the home and alternate care settings. For more information about the
Company, please visit www.korumedical.com.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; font-size:11pt; text-align: justify"><B><U>Forward-looking Statements</U></B></P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; font-size:11pt; text-align: justify">This press release may contain forward-looking statements that
involve risks and uncertainties. Actual results may differ materially from the results predicted and reported results should
not be considered as an indication of future performance. The potential risks and uncertainties that could cause actual
results to differ from the results predicted include, among others, those risks and uncertainties included under the captions
&ldquo;Risk Factors&rdquo; in our Annual Report on Form 10-K for the year ended December 31, 2019, as amended, and our most
recent Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, which are on file with the SEC and are
available on our website at www.korumedical.com/investors and on the SEC website at www.sec.gov. Additional information will
also be set forth in our Annual Report on Form 10-K for the year ended December 31, 2019. All information provided in this
release and in the attachments is as of February 25, 2020. Undue reliance should not be placed on the forward-looking
statements in this press release, which are based on information available to us on the date hereof. We undertake no duty to
update this information unless required by law.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; font-size:11pt"><B>Contacts:</B></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-size:11pt"><B>The Equity Group Inc.</B></P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="margin-top: 0px; font-size: 10pt"><TR height=0 style="font-size:1pt"><TD STYLE="width: 312px"></TD><TD STYLE="width: 312px"></TD></TR>
<TR><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px; font-size:11pt">Devin Sullivan</P>
</TD><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px; font-size:11pt">Kalle Ahl, CFA</P>
</TD></TR>
<TR><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px; font-size:11pt">Senior Vice President</P>
</TD><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px; font-size:11pt">Vice President</P>
</TD></TR>
<TR><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px; font-size:11pt">212-836-9608</P>
</TD><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px; font-size:11pt">212-836-9614</P>
</TD></TR>
<TR><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px; font-size:11pt">mailto:dsullivan@equityny.com</P>
</TD><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px; font-size:11pt">kahl@equityny.com</P>
</TD></TR>
</TABLE>
<P style="margin:0px" align=center><BR></P>

<HR noshade align="center" width="100%" size="2">
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>koru_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 koru_logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  \ , # 2(  A$! Q$!_\0
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M!\5/"T[O^#N]BO\ P42^!K+PR?L2^#&4]>5^.7Q_(_45\+_MC_\ !/GX^_\
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M&SX=[W_@T\_:M\2?&/\ 8?\ B;^S=XQU:?6-1_9%^)MEH_@::Y9IKC3O@O\
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M9_M/7EU,Q Q'%\%/&QV1J2/,GF;;#;PKF2>>2.&-6DD52 ?Q'?\ !H7_ ,I
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D$/ACXH^,^O\ C[Q'X!\!+JFCZ+J(UWQO\3/%'CG[:HHH __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
